COST MINIMISATION ANALYSIS IN CLINICAL PRACTICE OF RIBOCICLIB VERSUS PALBOCICLIB IN THE TREATMENT OF METASTASTIC BREAST CANCER

COST MINIMISATION ANALYSIS IN CLINICAL PRACTICE OF RIBOCICLIB VERSUS PALBOCICLIB IN THE TREATMENT OF METASTASTIC BREAST CANCER